Ibrutinib
Brand name: Imbruvica
Rank #18 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$875.8M
Total Cost
56,368
Total Claims
$875.8M
Total Cost
2,138
Prescribers
$16K
Cost per Claim
435
Beneficiaries
56,993
30-Day Fills
$410K
Avg Cost/Provider
26
Avg Claims/Provider
Share of Medicare Part D Spending
0.32%
of total Medicare Part D spending
$875.8M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $875.8M total
🔎 Data Overview
Ranked #18 out of 500 drugs tracked by total cost. Ibrutinib represents a significant portion of Medicare drug spending.
At $15,537 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $409,643 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Average cost of $2,013,373 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Ibrutinib
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Antoine Chahine | Medical Oncology | Canfield, OH | 181 | $3.0M |
| 2 | Thomas Kipps | Hematology-Oncology | La Jolla, CA | 187 | $2.9M |
| 3 | Wahid Hanna | Hematology-Oncology | Knoxville, TN | 159 | $2.1M |
| 4 | Heide Rodgers | Hematology-Oncology | Saint Louis, MO | 138 | $2.0M |
| 5 | Jose Sarriera | Hematology-Oncology | Orlando, FL | 113 | $2.0M |
| 6 | Noman Rafique | Hematology-Oncology | Massillon, OH | 113 | $1.9M |
| 7 | Mark Romer | Hematology-Oncology | Dayton, OH | 116 | $1.9M |
| 8 | Cheryl Kovalski | Hematology-Oncology | Lansing, MI | 102 | $1.8M |
| 9 | Danielle Brander | Hematology-Oncology | Durham, NC | 111 | $1.8M |
| 10 | Erin Pettijohn | Hematology-Oncology | Grand Rapids, MI | 128 | $1.7M |
| 11 | Robert Zielinski | Hematology | Williamsville, NY | 110 | $1.7M |
| 12 | John Graham | Hematology-Oncology | Canfield, OH | 102 | $1.7M |
| 13 | Lawrence Mendelsohn | Hematology-Oncology | Little Rock, AR | 103 | $1.7M |
| 14 | Nicholas Iannotti | Hematology-Oncology | Port St Lucie, FL | 99 | $1.7M |
| 15 | Lee Hicks | Medical Oncology | Lexington, KY | 106 | $1.6M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 15 | Enzalutamide (Xtandi) | $985.0M | 72,710 |
| 16 | Mirabegron (Myrbetriq) | $927.5M | 1,407,073 |
| 17 | Tirzepatide (Mounjaro) | $877.9M | 680,457 |
| 18 | Ibrutinib (Imbruvica) | $875.8M | 56,368 |
| 19 | Ustekinumab (Stelara) | $852.3M | 31,974 |
| 20 | Paliperidone Palmitate (Invega Sustenna) | $832.3M | 252,388 |
| 21 | Insulin Aspart (Novolog Flexpen) | $831.6M | 958,823 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology